In summary, the present study demonstrates that brostallicin-mediated cytotoxicity does not depend on the MMR status of tumour cells, and that, at least in p53-deficient mouse cells, functional ATM or DNA-PK is not required. The gene discussed is ATM; the disease is neoplasm.